Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Inhibrx typically reports earnings after market close, meaning Day 0 reflects anticipation before results are released, while Day +1 captures the market's first full reaction to the actual numbers and management commentary.

Historical price behavior around earnings has been volatile, with an average absolute Day 0 move of 4.29% and Day +1 move of 5.01%. The Day 0 trading range averages 7.51%, while Day +1 shows even wider swings at 10.35%, reflecting the biotech's clinical-stage nature and sensitivity to pipeline updates.

The most recent earnings report in August 2026 saw the stock decline 1.37% on Day 0, then drop 8.91% on Day +1 with a 9.33% intraday range—suggesting investors were disappointed despite the modest EPS beat. The May 2026 report showed similar weakness, with Day +1 declining 6.47% on a 14.13% range. Earlier reports in 2025 and late 2024 showed more mixed directional moves but consistently wide ranges, with several sessions exceeding 15% intraday volatility.

The pattern indicates that while the magnitude of moves has been substantial, direction has been unpredictable. Investors should expect significant volatility following this release, particularly given the high-stakes nature of updates on the ozekibart regulatory timeline and INBRX-106 development strategy.

Part 2.2: Options Market Expected Move

The options market is pricing a 6.73% expected move for the November 20 expiration, with an implied range of $82.49 to $94.39. This is notably higher than the historical average Day +1 move of 5.01% but below the average Day +1 range of 10.35%, suggesting options traders are anticipating above-average volatility but not an extreme outlier event relative to recent earnings history.

Part 3: What Analysts Are Saying

Current Analyst Consensus

Analysts maintain a bullish stance on Inhibrx, with 3 Strong Buy ratings and 2 Hold ratings among the 5 analysts covering the stock. The average recommendation of 4.20 out of 5.00 reflects strong conviction in the company's clinical pipeline and commercial potential. The consensus price target of $266.67 implies substantial upside from the current price of $87.75, with individual targets ranging from a low of $230.00 to a high of $325.00.

Sentiment Evolution

Analyst sentiment has remained unchanged over the past month, with the rating distribution and average recommendation holding steady at 4.20. This stability comes despite the company's significant clinical progress with INBRX-106 in September, suggesting analysts had already incorporated positive expectations into their models or are waiting for additional regulatory clarity before upgrading.

The wide range in price targets—spanning nearly $100—reflects differing views on probability-weighted outcomes for the two lead programs. The high-end targets likely assume successful commercialization of both ozekibart and INBRX-106, while more conservative targets may discount execution risk or assign lower probabilities to the accelerated approval pathway for INBRX-106.

Upside Potential

The consensus target of $266.67 represents 204% upside from current levels, an unusually large implied return that underscores both the transformational potential of the pipeline and the binary nature of clinical-stage biotech investing. The bullish case hinges on ozekibart approval in April 2027 as the first treatment for chondrosarcoma and successful execution of the INBRX-106 development plan in head and neck cancer and potentially broader immunogenic tumor types.

Part 4: Technical Picture

The Barchart Technical Opinion currently shows a 56% Sell signal, strengthening from 40% Sell one week ago and 8% Sell one month ago. This deterioration in technical sentiment has accelerated recently, with the signal moving decisively more bearish over the past week as the stock has declined heading into earnings.

Timeframe Analysis

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum has turned negative as the stock approaches earnings
• Medium-term (50% Sell): Moderate sell signal suggests consolidation or weakness in the intermediate timeframe
• Long-term (50% Sell): Moderate sell signal reflects pressure in the longer-term trend structure

Trend Characteristics: The trend is characterized as Weak and Strengthening, indicating that while the bearish bias is not yet extreme, selling pressure has been building momentum heading into the earnings release.

The stock is trading at $87.75, positioned above its 10-day ($83.73) and 20-day ($86.60) moving averages, but below its 5-day ($89.04), 50-day ($96.05), 100-day ($96.09), and 200-day ($92.64) moving averages. This mixed picture shows short-term resilience against longer-term downward pressure.

The technical setup heading into earnings is cautionary, with the stock caught between short-term support and longer-term resistance. The fact that INBX is trading below all major longer-term moving averages (50-day, 100-day, 200-day) despite significant positive clinical news in September suggests the market may be pricing in execution risk or concerns about the path to commercialization.

The strengthening sell signal and weak trend characteristics indicate technical momentum is working against the stock. However, the proximity to the 20-day moving average at $86.60 provides nearby support, while the 50-day at $96.05 represents overhead resistance. Given the high options-implied volatility and historical earnings behavior, traders should expect a decisive move in either direction that could quickly test these technical levels. The bearish technical backdrop may create an asymmetric setup where positive fundamental news could trigger an outsized reversal, while disappointing updates could accelerate the existing downtrend.